|
293 Companies |
|
490 Products |
|
490 Products |
|
199 Mechanisms of Action |
|
25 Trials |
|
7787 News |
|
| «12...8384858687888990919293...156157» |
- Enrollment open: Sequencing T-cells in Type I Diabetes Mellitus (clinicaltrials.gov) - Sep 30, 2014
P=N/A, N=60, Recruiting, Sponsor: Seton Family of Hospitals
Not yet recruiting --> Recruiting
- | Tresiba (insulin degludec) / Novo Nordisk
Enrollment closed: SWITCH 1: A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Sep 30, 2014
P3, N=446, Active, not recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche
Enrollment closed: Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations (clinicaltrials.gov) - Sep 30, 2014
P1, N=10, Active, not recruiting, Sponsor: Johns Hopkins University
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion, Trial primary completion date: An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies (clinicaltrials.gov) - Sep 30, 2014
P3, N=2067, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Aug 2013 --> Apr 2013
- || Betaseron (IFN-β-1b) / Bayer
Trial primary completion date, HEOR: BetaSleep: Investigating the Relationship Between Sleep, Quality of Life,Other Disorders and Therapies in MS Patients on Betaferon (clinicaltrials.gov) - Sep 29, 2014
P=N/A, N=300, Recruiting, Sponsor: Bayer
Active, not recruiting --> Completed | Trial primary completion date: Aug 2013 --> Apr 2013 Trial primary completion date: Dec 2015 --> Dec 2016
- ||| Benlysta (belimumab) / GSK
Trial initiation date: A Phase 2B Open-Label, Single-Arm, Repeat-Dose Study to Evaluate the Reliability of an Autoinjector (clinicaltrials.gov) - Sep 29, 2014
P2b, N=100, Recruiting, Sponsor: GlaxoSmithKline
Trial primary completion date: Dec 2015 --> Dec 2016 Initiation date: May 2014 --> Sep 2012
- ||| Zinbryta (daclizumab) / Biogen, AbbVie
Enrollment change, Trial primary completion date, Monotherapy: SELECTED: Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis (clinicaltrials.gov) - Sep 29, 2014
P2, N=410, Active, not recruiting, Sponsor: Biogen Idec
Initiation date: May 2014 --> Sep 2012 N=600 --> 410 | Trial primary completion date: May 2015 --> Jan 2018
- ||||| New P2 trial: Efficacy and Safety of BIIL 284 BS in Adult Patients With Active Rheumatoid Arthritis (clinicaltrials.gov) - Sep 29, 2014
P2, N=404, Completed, Sponsor: Boehringer Ingelheim
- |||| vatelizumab (GBR 500) / Glenmark
Enrollment open: Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis (clinicaltrials.gov) - Sep 29, 2014
P2, N=168, Recruiting, Sponsor: Genzyme, a Sanofi Company
N=600 --> 410 | Trial primary completion date: May 2015 --> Jan 2018 Not yet recruiting --> Recruiting
- ||||| NI-071 (infliximab biosimilar) - Sanofi, Nichi / Iko, Binex, Aprogen, Elea Labs
Enrollment closed: A Phase 3 Study of NI-071 in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Sep 29, 2014
P3, N=230, Active, not recruiting, Sponsor: Nichi-Iko Pharmaceutical Co.,Ltd.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||| Zinbryta (daclizumab) / Biogen, AbbVie
Trial primary completion date: An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (clinicaltrials.gov) - Sep 29, 2014
P3, N=133, Active, not recruiting, Sponsor: Biogen Idec
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2016 --> Apr 2013
- | Aspart-PH20 (insulin aspart/rHuPH20) / Halozyme, Lispro-PH20 (insulin lispro/rHuPH20) / Halozyme
Trial completion: Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase (clinicaltrials.gov) - Sep 29, 2014
P4, N=25, Completed, Sponsor: Halozyme Therapeutics
Trial primary completion date: Dec 2016 --> Apr 2013 Active, not recruiting --> Completed
- | Trial completion, Enrollment change: The Impact of Fitness on Vascular Dysfunction in Adolescents With Type 1 Diabetes (clinicaltrials.gov) - Sep 29, 2014
P=N/A, N=32, Completed, Sponsor: University of Virginia
Active, not recruiting --> Completed Recruiting --> Completed | N=40 --> 32
- |||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Retinal and Retinal Pigment Epithelium (RPE) Autoimmunity in Age-related Macular Degeneration (AMD) (clinicaltrials.gov) - Sep 29, 2014
P2, N=131, Completed, Sponsor: Lawrence S. Morse, MD
Recruiting --> Completed | N=40 --> 32 Active, not recruiting --> Completed
- |||| Actemra SC (tocilizumab SC) / Roche, Halozyme
Trial primary completion date, Combination therapy, Monotherapy: OSCAR: A Study on Safety and Efficacy of Tocilizumab (RoActemra/Actemra) Alone or in Combination With Non-Biologic Antirheumatics in Participants With Rheumatoid Arthritis (clinicaltrials.gov) - Sep 28, 2014
P3, N=150, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Trial primary completion date: Nov 2015 --> Jul 2015
- Orencia (abatacept) / BMS
Trial primary completion date: Ultrasound Scores as Indication of Response to Subcutaneous Abatacept in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Sep 28, 2014
P3, N=25, Active, not recruiting, Sponsor: University of California, Los Angeles
Trial primary completion date: Nov 2015 --> Jul 2015 Trial primary completion date: Feb 2014 --> Feb 2013
- | Trial termination: Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression (clinicaltrials.gov) - Sep 28, 2014
P4, N=54, Terminated, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Feb 2014 --> Feb 2013 Completed --> Terminated; Due to slow enrollment the study was terminated early
- Clinical: Autoimmune Diseases And Serum Anti-Nuclear Antibodies Positivity In Non-Celiac Wheat Sensitivity Patients (clinicaltrials.gov) - Sep 28, 2014
P=N/A, N=90, Completed, Sponsor: University of Palermo
- ||| Betaseron (IFN-β-1b) / Bayer
Adherence: BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon (clinicaltrials.gov) - Sep 28, 2014
P=N/A, N=450, Not yet recruiting, Sponsor: Bayer
- autologous mesenchymal stem cells / Tianjin Medical University General Hospital
New P2 trial: Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders (clinicaltrials.gov) - Sep 28, 2014
P2, N=15, Recruiting, Sponsor: Tianjin Medical University General Hospital
- Ninlaro (ixazomib) / Takeda
Enrollment open: Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib in Lupus Nephritis (LN) (clinicaltrials.gov) - Sep 28, 2014
P1, N=40, Recruiting, Sponsor: Takeda
Completed --> Terminated; Due to slow enrollment the study was terminated early Not yet recruiting --> Recruiting
- ||| Betaseron (IFN-β-1b) / Bayer
Trial completion, Adherence: Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH) (clinicaltrials.gov) - Sep 28, 2014
P=N/A, N=735, Completed, Sponsor: Bayer
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Trial primary completion date: Transcranial Direct Current Stimulation on Cortical Plasticity in Patients With Anti-NMDA Receptor Encephalitis (clinicaltrials.gov) - Sep 28, 2014
P=N/A, N=40, Recruiting, Sponsor: Charite University, Berlin, Germany
Active, not recruiting --> Completed Trial primary completion date: Dec 2014 --> May 2015
- | Trial termination: A Study of CellCept (Mycophenolate Mofetil) in Patients With Lupus Nephritis. (clinicaltrials.gov) - Sep 28, 2014
P3, N=52, Terminated, Sponsor: Hoffmann-La Roche
Trial primary completion date: Dec 2014 --> May 2015 Completed --> Terminated; Study was terminated early for administrative reasons.
- ||| Clinical: E3: Adult Accuracy Study of the Enlite 3 Glucose Sensor (clinicaltrials.gov) - Sep 28, 2014
P=N/A, N=100, Not yet recruiting, Sponsor: Medtronic Diabetes
- tramadol hydrochloride / Generic mfg.
New P4 trial: Influence of Diabetes on Tramadol Pharmacokinetics (clinicaltrials.gov) - Sep 28, 2014
P4, N=30, Completed, Sponsor: Universidade Estadual Paulista J
- Enrollment open: Consolidation & Interference in Multiple Sclerosis (clinicaltrials.gov) - Sep 28, 2014
P=N/A, N=72, Recruiting, Sponsor: Kessler Foundation
Completed --> Terminated; Study was terminated early for administrative reasons. Not yet recruiting --> Recruiting
- Trial primary completion date: Rheumatoid Arthritis:Tolerance Induction by Mixed Chimerism (clinicaltrials.gov) - Sep 28, 2014
P1, N=12, Recruiting, Sponsor: Northwestern University
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2015 --> Sep 2016
- Campath (alemtuzumab) / Sanofi
Trial primary completion date: Allogeneic Stem Cell Transplantation in Systemic Lupus Erythematosus (clinicaltrials.gov) - Sep 28, 2014
P1, N=10, Recruiting, Sponsor: Northwestern University
Trial primary completion date: Sep 2015 --> Sep 2016 Trial primary completion date: Dec 2015 --> Dec 2016
- Xeljanz (tofacitinib) / Pfizer
Clinical: Pharmacokinetics Of CP-690,550 In Pediatric Patients With Juvenile Idiopathic Arthritis (JIA) (clinicaltrials.gov) - Sep 28, 2014
P1, N=24, Recruiting, Sponsor: Pfizer
Trial primary completion date: Dec 2015 --> Dec 2016 Initiation date: Dec 2012 --> Mar 2013
- omeprazole / Generic mfg., cyclosporine / Generic mfg.
Phase classification: The Insulin Independence Trial (IIT) Evaluating the Safety and Efficacy of Oral Cyclosporine and Oral Omeprazole for Insulin Independence Among Recent Onset Type 1 Diabetes Patients (clinicaltrials.gov) - Sep 28, 2014
P3, N=130, Not yet recruiting, Sponsor: Perle Bioscience, Inc.
Initiation date: Dec 2012 --> Mar 2013 Phase classification: P2/3 --> P3
- | New P1 trial, PK/PD data: Pharmacokinetics, Safety and Efficacy of BIIL 284 BS in Patients With Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Sep 28, 2014
P1, N=26, Completed, Sponsor: Boehringer Ingelheim
- |||| Lemtrada (alemtuzumab) / Sanofi
Clinical: EMERALD: Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA (clinicaltrials.gov) - Sep 28, 2014
P4, N=56, Recruiting, Sponsor: Genzyme, a Sanofi Company
Phase classification: P2/3 --> P3 Not yet recruiting --> Recruiting
- | Trial completion, Trial primary completion date: Continuous Glucose Monitoring in Adolescents With Poorly Controlled Type 1 Diabetes (clinicaltrials.gov) - Sep 28, 2014
P=N/A, N=26, Completed, Sponsor: Nemours Children's Clinic
Not yet recruiting --> Recruiting Recruiting --> Completed | Trial primary completion date: Jun 2013 --> Jun 2014
- prednisone / Generic mfg.
Trial completion: PRNC: Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg (clinicaltrials.gov) - Sep 28, 2014
P3, N=40, Completed, Sponsor: Centre Hospitalier Universitaire de Saint Etienne
Recruiting --> Completed | Trial primary completion date: Jun 2013 --> Jun 2014 Recruiting --> Completed
- Trial completion, Enrollment change: Assessment of Beta Cell Mass by PET Scans With [11C] Dihydrotetrabenazine (DTBZ) in Longstanding Type 1 Diabetes. (clinicaltrials.gov) - Sep 28, 2014
P=N/A, N=18, Completed, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting --> Completed Enrolling by invitation --> Completed | N=30 --> 18
- Sativex (nabiximols) / Jazz
P3 data, Trial primary completion date: Phase 3, 28-week, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of Nabiximols as an add-on Therapy in Subjects With Spasticity Due to Multiple Sclerosis. (clinicaltrials.gov) - Sep 22, 2014
P3, N=711, Not yet recruiting, Sponsor: GW Research Ltd
Enrolling by invitation --> Completed | N=30 --> 18 Trial primary completion date: Dec 2016 --> Jun 2017
- || Trial primary completion date: Shared Decision Making in Graves Disease - Graves Disease (GD) Choice (clinicaltrials.gov) - Sep 22, 2014
P=N/A, N=147, Recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Dec 2016 --> Jun 2017 Trial primary completion date: Jul 2014 --> Dec 2014
- || Saphnelo (anifrolumab) / AstraZeneca
Trial primary completion date: MUSE: A Study of the Efficacy and Safety of MEDI-546 in Systemic Lupus Erythematosus (clinicaltrials.gov) - Sep 22, 2014
P2, N=626, Active, not recruiting, Sponsor: MedImmune LLC
Trial primary completion date: Jul 2014 --> Dec 2014 Trial primary completion date: Apr 2015 --> Aug 2014
- Enrollment closed, Trial primary completion date: Full Day and Night Closed-Loop With DiAs Platform (clinicaltrials.gov) - Sep 22, 2014
P=N/A, N=48, Active, not recruiting, Sponsor: University of Virginia
Trial primary completion date: Apr 2015 --> Aug 2014 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2014 --> Feb 2015
- ||| vobarilizumab (ALX-0061) / Sanofi
Trial completion, IO biomarker: ALX-0061 Phase I Bioavailability Study in Healthy Volunteers (clinicaltrials.gov) - Sep 22, 2014
P1, N=70, Completed, Sponsor: Ablynx
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2014 --> Feb 2015 Recruiting --> Completed
- Promacta (eltrombopag) / Novartis
Trial primary completion date: Promacta Pregnancy Registry (clinicaltrials.gov) - Sep 19, 2014
P=N/A, N=1, Recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Completed Trial primary completion date: Jan 2015 --> Jan 2016
- Enrollment closed: A Study of Intracellular Signaling in Muscle and Fat Cells During Ketosis (clinicaltrials.gov) - Sep 19, 2014
P=N/A, N=9, Active, not recruiting, Sponsor: University of Aarhus
Trial primary completion date: Jan 2015 --> Jan 2016 Recruiting --> Active, not recruiting
- ||||| tabalumab (LY2127399) / Eli Lilly
Enrollment closed: Illuminate-Xt: On Open-Label Study in Participants With Systemic Lupus Erythematosus (clinicaltrials.gov) - Sep 19, 2014
P3, N=1276, Active, not recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting Enrolling by invitation --> Active, not recruiting
- Trial primary completion date: Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias. (clinicaltrials.gov) - Sep 19, 2014
P=N/A, N=40, Recruiting, Sponsor: Beth Israel Medical Center
Enrolling by invitation --> Active, not recruiting Trial primary completion date: Oct 2014 --> Apr 2015
- | New P1 trial: Safety Study of Immune System Modulator for Autoimmune Diseases (clinicaltrials.gov) - Sep 19, 2014
P1, N=18, Active, not recruiting, Sponsor: Artax Biopharma Inc
- Novolin R (recombinant human insulin) / Novo Nordisk
Enrollment open, Trial primary completion date: Pilot Study Investigating the Feasibility of Determining the Endogenous Glucose Production During a Hypoglycaemia (clinicaltrials.gov) - Sep 19, 2014
P2, N=20, Enrolling by invitation, Sponsor: Medical University of Graz
Trial primary completion date: Oct 2014 --> Apr 2015 Not yet recruiting --> Enrolling by invitation | Trial primary completion date: Jun 2014 --> Dec 2014
- Enrollment open: A Trial to Compare the PK and PD of Insulin Lispro Administered Into Different Tissues in Subjects With Diabetes Mellitus Type 1 (clinicaltrials.gov) - Sep 19, 2014
P2, N=13, Recruiting, Sponsor: Profil Institut f
Not yet recruiting --> Enrolling by invitation | Trial primary completion date: Jun 2014 --> Dec 2014 Not yet recruiting --> Recruiting
- Trial completion: Artificial Pancreas Control System in an Inpatient Setting (clinicaltrials.gov) - Sep 19, 2014
P2, N=14, Completed, Sponsor: Legacy Health System
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | TNF-? kinoid / Neovacs, Debiopharm
Trial completion: Immunogenicity and Safety of TNFa Kinoid in Rheumatoid Arthritis With Secondary Resistance to TNFa Antagonists (clinicaltrials.gov) - Sep 19, 2014
P2, N=40, Completed, Sponsor: Neovacs
Active, not recruiting --> Completed Active, not recruiting --> Completed